Background: Machine learning (ML) offers opportunities to overcome limitations of conventional survival analyses, which are commonly found in cancer studies. However, the choice and levels of performance of ML methods vary across studies. As a result, it is unclear whether they consistently outperform traditional statistical methods and whether one particular ML strategy may outperform others for survival analysis. The present study aimed to systematically review the literature around this emerging topic. Methods: This systematic review was conducted using the PRISMA guidelines. Electronic databases were systematically searched using keywords related to Machine Learning, Survival Analysis and Cancer. Results & Conclusion: The review included 196 studies, from which 39 comparable studies were used for the analysis. Improved predictive performance was seen from the use of ML in almost all cancer types. Predictive performance of the different ML methods varied across cancer types, and multi‐task and deep learning methods appeared to yield superior performance; however, it was reported in only a minority of papers. This study also highlighted great variability in both methodologies and their implementations.

Predicting the risk of, and time to biochemical recurrence (BCR) in prostate cancer patients post-operatively is critical in patient treatment decision pathways following surgical intervention. This study aimed to investigate the predictive potential of mRNA information to improve upon reference nomograms and clinical-only models, using a dataset of 187 patients that includes over 20,000 features. Several machine learning methodologies were implemented for the analysis of censored patient follow-up information with such high-dimensional genomic data. Our findings demonstrated the potential of inclusion of mRNA information for BCR-free survival prediction. A random survival forest pipeline was found to achieve high predictive performance with respect to discrimination, calibration, and net benefit. Two mRNA variables, namely ESM1 and DHAH8, were identified as consistently strong predictors with this dataset.

Technological innovation yielded opportunities to obtain mRNA expression data for prostate cancer (PCa) patients even prior to biopsy, which can be used in a precision medicine approach to treatment decision-making. This can apply in particular to predict the risk of, and time to biochemical recurrence (BCR). Most mRNA-based models currently proposed to this end are designed for risk classification and post-operative prediction. Effective pre-operative prediction would facilitate early treatment decision-making, in particular by indicating more appropriate therapeutic pathways for patient profiles who would likely not benefit from a systematic prostatectomy regime. The aim of this study is to investigate the possibility to leverage mRNA information pre-operatively for BCR-free survival prediction. To do this, we considered time-to-event machine learning (ML) methodologies, rather than classification models at a specific survival horizon. We retrospectively analysed a cohort of 135 patients with clinical follow-up data and mRNA information comprising over 26,000 features (data accessible at NCBI GEO database, accession GSE21032). The performance of ML models including random survival forest, boosted and regularised Cox models were assessed, in terms of model discrimination, calibration, and predictive accuracy for overall, 3-year and 5-year survival, aligning with common clinical endpoints. Results showed that the inclusion of mRNA information could yield a gain in performance for pre-operative BCR prediction. ML-based time-to-event models significantly outperformed reference nomograms that used only routine clinical information with respect to all metrics considered. We believe this is the first study proposing pre-operative transcriptomics models for BCR prediction in PCa. External validation of these findings, including confirmation of the mRNA variables identified as potential key predictors in this study, could pave the way for pre-operative precision nomograms to facilitate timely personalised clinical decision-making.

Introduction: The win-ratio has great potential for determining the overall efficacy of treatments and therapies in clinical trials, as its ability to hierarchically account for multiple endpoints provides a holistic metric of the treatment effect. For the win-ratio to become a prominent and reliable statistical method outside of cardiovascular disease, a straightforward approach to study design, particularly in terms of power and sample size determination, is needed. Methods: Using an appropriate method for determining these metrics is vital to ensure the validity of the results obtained in a study. Results: The WRestimates package provides easy-to-use functions that can be used for determining the required sample size and power of studies implementing the win-ratio. Conclusion: These methods enable the calculation of sample size and power based on estimands or pilot data, thereby eliminating the need for complex simulation-based methods that require numerous assumptions about the data.